Platform Comparison Guide

Envision vs OptiLight
The clear choice.

A detailed, data-driven guide to help you make the right investment for your practice.

$770
Lumenis cost per patient (USD)
40%
Greater IPL efficacy (500-600nm)
50+
OptiLight accounts switched to Envision
1,050+
Envision operators worldwide
Side by Side

Feature Comparison

A detailed breakdown across every metric that matters to your practice.

Category InMode Envision Lumenis OptiLight + OptiPlus
Platform Single integrated workstationIPL (Lumecca-I) + RF (Forma-I) purpose-built together Two separate machines requiredOptiLight IPL + OptiPlus (rebranded NuEra body device)
IPL Technology Lumecca — left-shift focused40% greater efficacy at 500-600nm where it matters most for inflammation, rosacea, telangiectasia Standard IPL spectrum (400-1200nm)Same spectrum as previous M22 — wave-style effect capturing only 10-15% at effective wavelengths
RF for Dry Eye Forma-I — purpose-built for periorbitalClosed-circuit loop at 2mm depth — exactly where meibomian glands are. Proven neo-collagenic Off-label, no dry eye certificationNuEra body contouring device rebranded. 10mm electrodes — far too wide for eyelids. Monopolar penetrates 5-10mm — too deep
RF Periorbital Use Indicated for MGD / periorbital Not indicated for MGD / periorbitalLumenis clinical team tells doctors bipolar is "unsafe" around eyes
Consumables per Patient Minimal consumable costsStandard ultrasound gel only $770 USD per patient (series of 4)Tips, shields, grounding pads, NuRevital cream, recalibration fees all add up
Handpiece Longevity No hard pulse cutoff Hard cutoff at 75,000 pulsesOptiLight: $12K USD to replace. OPT: $25K USD to replace. Only 94 patients before replacement needed.
Warranty Comprehensive coverage 1 year or 40K pulses onlyExtended service: $6K-$20K USD annually. Work orders: $4K-$10K per visit
Patient Comfort Not painful for patientsDr. Jennifer Tsai confirms significantly better patient experience Reported as painfulOptiLight treatments reported as uncomfortable by patients
Ease of Use No filter changes neededSimple, intuitive operation Filter changes requiredOPT connects via fragile Bluetooth dongle — frequently fails if device bumps into wall
Reliability Robust, minimal downtime OPT frequently fails in Year 1Most users report issues with OPT handpiece within first year. Causes clinic downtime and rescheduling
Post-Sale Support Master Class program + CLINICL AIImplementation training, profitability coaching, and 24/7 CLINICL AI for exact device settings, patient-specific protocols, and round-the-clock support No post-sale supportNo sales training, no consultation aid. 2 rounds of layoffs in Q4 2023. Virtual-only national meetings
Market Momentum Fastest growing med-tech brand1,050+ operators worldwide. 50+ OptiLight accounts have switched to Envision in 6 months Declining momentumBudget cuts, layoffs, potential acquisition. Lower Google Trends interest vs Lumecca
Cost Analysis

Total Cost of Ownership

Adjust the patient volume to see the real cost difference over time.

How many patients will you treat?

Drag the slider to model your expected patient volume (series of 4 treatments each)

Number of Patients (series of 4 treatments)
100
InMode Envision — Extended Costs
$0
Minimal consumable costs
Lumenis OptiLight + OptiPlus — Extended Costs
$77,000
$770 USD per patient
Your Practice Saves
$77,000
by choosing Envision over OptiLight + OptiPlus

Lumenis RF + IPL Cost Breakdown (per patient, USD)

OPT Tip consumable$100
OptiLight handpiece replacement$128
OPT handpiece replacement$266
Recalibration share$18
Eye shields (sticky)$7
NuRevital cream$6
Monopolar grounding pad$100
RF eye shields$147
TOTAL PER PATIENT$770

Extended Cost at Scale (USD)

50 patients
$0
$38,500
100 patients
$0
$77,000
150 patients
$0
$115,500
200 patients
$0
$154,000
Envision
OptiLight + OptiPlus
Clinical Science

Why RF + IPL Together Matters

80% of dry eye is meibomian gland dysfunction. IPL alone treats the surface — RF reaches the glands.

Treatment Depth Comparison

Meibomian glands sit at 2mm depth. Only Envision's Forma-I reaches them.

Gland Depth
2.0mm
Target zone
Forma-I RF
2.0mm
Exact match
OptiPlus RF
5-10mm
Too deep
The Analogy

"You can stop putting hair down the drain, but if you don't roto-rooter the clog, it still won't work right."

IPL stops inflammation (the hair). RF unclogs the glands (the drain). You need both.

The Science

IPL = optical energy at 300nm depth. Targets inflammation, reds, browns in the epidermis. Not regenerative — zero studies show IPL stimulates collagen.

RF = electrical energy at 2mm depth. Proven neo-collagenic across dermatology, physiotherapy. Hundreds of studies confirm tissue regeneration.

Lumecca IPL Advantage
40% Greater efficacy at 500-600nm

Lumecca's left-switch focused IPL concentrates most energy between 400-600nm — the exact wavelengths that clear neovascular blood vessels, inflammation, rosacea, and telangiectasia. Standard IPL (including OptiLight) uses a wave-style effect capturing only 10-15% at these critical wavelengths.

Educational Video

Lumecca-I vs Other IPLs — The Critical Differences

Learn the basic science of IPL and what makes Lumecca unique from every other IPL on the market.

Watch Video
Common Questions

Questions We Hear Most

Click any question for a detailed, data-backed answer.

"Doesn't OptiLight have FDA indication for dry eye?"
OptiLight uses the exact same IPL spectrum (400-1200nm) as any standard IPL — including their previous M22. There are no changes in spectrum output. If you read their research papers, they're all cited to M22. Envision already has FDA indication and is approved in Canada. The indication doesn't change the physics — and Lumecca delivers 40% greater efficacy at the wavelengths that actually matter (500-600nm).
"Is RF really necessary for dry eye treatment?"
If RF isn't necessary, why did Lumenis rush to market with a rebranded body contouring device? IPL penetrates to 300nm — glands are at 2mm. There is zero published evidence that IPL stimulates collagen or regenerates gland tissue. RF is proven neo-collagenic across hundreds of studies in dermatology and physiotherapy. Ask any doctor with IPL — they'll tell you results are best when paired with RF thermal expression. That's why IPL-only practices are their biggest buyers for RF devices.
"Can OptiPlus handle RF for periorbital use?"
OptiPlus is the NuEra body contouring device repackaged. It was never certified for periorbital use. Their own clinical team tells doctors the bipolar setting is "unsafe" around the eyes. The monopolar handpiece uses 10mm electrodes — far too wide for an eyelid — and penetrates 5-10mm, well past the dermis where there's no positive outcome data. Envision's Forma-I was purpose-built for periorbital treatment with a closed-circuit loop at exactly 2mm.
"OptiLight has been around longer — isn't that safer?"
Lumenis went through 2 rounds of layoffs in Q4 2023. Their corporate team was told to use PTO before March 31st due to potential acquisition. They held a virtual-only national sales meeting because financials couldn't support in-person. They offer no post-sale support, no sales training, no Master Class program. Meanwhile, 50+ US OptiLight accounts have switched to Envision in just 6 months — including top speakers like Dr. Jennifer Tsai.
"What about the upfront investment?"
Look at total cost of ownership. Lumenis consumables add $770 USD per patient across tips, shields, grounding pads, cream, handpiece replacements, and recalibration fees. At 100 patients, that's $77,000 in hidden costs. At 200 patients, $154,000. Plus, the OptiLight handpiece hard-caps at 75,000 pulses — that's only 94 patients before a $12K replacement. Envision's total cost of ownership is dramatically lower.
"What about the OPT spot-size handpiece?"
The OPT connects via a fragile Bluetooth dongle that frequently fails if the device bumps into a wall. Most users report issues within the first year — causing downtime, rescheduled patients, and lost revenue. It also has a 75,000 pulse hard cutoff costing $25,000 USD to replace — that's $266 per patient just for the handpiece. And it's the only "new" thing vs the old M22.
"Doesn't deeper RF penetration mean better results?"
This is a key misconception. Meibomian glands are at 2mm depth. Going deeper than 4mm puts you below the dermis — an area with no positive impact on outcomes. OptiPlus monopolar penetrates 5-10mm with electrodes separated by 10mm. That's designed for body contouring, not delicate periorbital tissue. Forma-I's closed-circuit loop targets exactly 2mm — right where the glands are.
"My patients are already seeing results with IPL alone"
Doctors love their IPL results — but clinical studies confirm outcomes are best when paired with RF thermal expression. That's because IPL handles surface inflammation while RF addresses the root cause: blocked meibomian glands. Why not get both with Envision from day one? Our operators report 100% patient satisfaction and practices grossing $200K in monthly revenue. What does your Lumenis profitability structure look like in comparison?
Practitioners Who Switched

Practices That Made the Switch

50+ OptiLight accounts have chosen Envision since its US soft launch.

OptiLight → Envision Converts

39 accounts listed
Line of Sight
NYC, NY — Dr. Jennifer Tsai OD
Airis Eye
Bellevue, WA
Precision Eye
Vancouver, WA
Amara Medical Aesthetic
Bellevue, WA
Gee Eye Care
Missouri City, TX
Memorial Park Vision
Houston, TX
Lahiri Eye Center
Donaldsonville, LA
Eye Care Plus
Amarillo, TX
Vision Plaza
Burleson, TX
Benjamin Eye Institute
Los Angeles, CA
Mather Vision
Lafayette, IN
ClearVue EyeCare
St. John, IN
Independent Eyes
Rapid City, SD
Woodley Optometry
Encino, CA
Pack Optical
Fort Worth, TX

Showing 15 of 39+ verified accounts. Additional accounts available upon request.

Key Opinion Leader

"Very effective, wide range coverage and front loaded. Easy to use and much simpler — no need for filter changes. Not painful for patients unlike OptiLight."

Dr. Jennifer Tsai, OD

Line of Sight, NYC — Former OptiLight user, switched to Envision

All data in this guide is sourced from published specifications and clinical market research.

View Source Research Document